Senhwa Biosciences Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Senhwa Biosciences.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	37.9%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Analysts Are Optimistic We'll See A Profit From Senhwa Biosciences, Inc. (GTSM:6492)

Mar 18

Recent updates

Analysts Are Optimistic We'll See A Profit From Senhwa Biosciences, Inc. (GTSM:6492)

Mar 18

Does This Valuation Of Senhwa Biosciences, Inc. (GTSM:6492) Imply Investors Are Overpaying?

Jan 19

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Senhwa Biosciences no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

TPEX:6492 - Estimaciones futuras de los analistas y datos financieros pasados (TWD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2024	1	-286	-275	-273	N/A
12/31/2023	1	-296	-291	-286	N/A
9/30/2023	1	-305	-328	-323	N/A
6/30/2023	1	-312	-329	-324	N/A
3/31/2023	1	-345	-379	-374	N/A
12/31/2022	1	-350	-400	-400	N/A
9/30/2022	1	-340	-375	-374	N/A
6/30/2022	1	-345	-374	-374	N/A
3/31/2022	1	-316	-337	-337	N/A
12/31/2021	1	-329	-300	-300	N/A
9/30/2021	1	-328	-329	-329	N/A
6/30/2021	1	-358	-287	-286	N/A
3/31/2021	1	-362	-291	-290	N/A
12/31/2020	1	-355	-273	-273	N/A
9/30/2020	1	-352	-249	-249	N/A
6/30/2020	0	-316	-294	-294	N/A
3/31/2020	0	-339	-303	-303	N/A
12/31/2019	0	-391	-385	-385	N/A
9/30/2019	0	-410	-393	-393	N/A
6/30/2019	1	-416	-397	-396	N/A
3/31/2019	1	-451	-416	-415	N/A
12/31/2018	1	-376	-375	-374	N/A
9/30/2018	1	-394	-348	-347	N/A
6/30/2018	0	-416	-386	-381	N/A
3/31/2018	0	-354	-351	-346	N/A
12/31/2017	N/A	-372	N/A	-326	N/A
9/30/2017	N/A	-333	N/A	-314	N/A
6/30/2017	0	-283	N/A	-255	N/A
3/31/2017	0	-286	N/A	-250	N/A
12/31/2016	0	-255	N/A	-221	N/A
9/30/2016	0	-233	N/A	-216	N/A
6/30/2016	N/A	-212	N/A	-198	N/A
3/31/2016	N/A	-194	N/A	-179	N/A
12/31/2015	N/A	-194	N/A	-174	N/A
9/30/2015	2	-180	N/A	-171	N/A
6/30/2015	5	-182	N/A	-173	N/A
3/31/2015	14	-165	N/A	-157	N/A
12/31/2014	24	-157	N/A	-141	N/A
9/30/2014	31	-139	N/A	-124	N/A
6/30/2014	39	-120	N/A	-106	N/A
3/31/2014	32	-117	N/A	-101	N/A
12/31/2013	26	-113	N/A	-96	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de 6492 es superior a la tasa de ahorro (0.8%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de 6492 crezcan más rápidamente que el mercado TW

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de 6492 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de 6492 crezcan más rápidamente que el mercado de TW.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de 6492 crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 6492 se prevé que sea elevada dentro de 3 años.

Senhwa Biosciences Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

No longer forecast to breakeven

Price target decreased to NT$143

Forecast breakeven date pushed back to 2022

Analysts Are Optimistic We'll See A Profit From Senhwa Biosciences, Inc. (GTSM:6492)

Recent updates

First quarter 2024 earnings released: NT$0.71 loss per share (vs NT$0.82 loss in 1Q 2023)

Senhwa Biosciences, Inc. to Report Q1, 2024 Results on May 13, 2024

Senhwa Biosciences, Inc., Annual General Meeting, Jun 21, 2024

Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan

Full year 2023 earnings released: NT$3.32 loss per share (vs NT$3.92 loss in FY 2022)

Senhwa Biosciences, Inc. Decides to Early Terminate the Phase II study of Silmitasertib to treat hospitalized patients with COVID-19

Senhwa Biosciences Receives Taiwan FDA IND Approval for Phase Ii Study of Silmitasertib in Patients with Community-Acquired Pneumonia (Cap) Associated with Viral Infection

Third quarter 2023 earnings released: NT$0.84 loss per share (vs NT$0.93 loss in 3Q 2022)

Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19

New minor risk - Share price stability

Senhwa Biosciences Announces Investigational New Drug Submission to U.S. Food and Drug Administration for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection

First half 2023 earnings released: NT$1.54 loss per share (vs NT$1.96 loss in 1H 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: NT$0.93 loss per share (vs NT$0.97 loss in 3Q 2021)

Third quarter 2022 earnings released: NT$0.93 loss per share (vs NT$0.97 loss in 3Q 2021)

Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer

First half 2022 earnings released: NT$1.96 loss per share (vs NT$1.78 loss in 1H 2021)

Senhwa Biosciences, Inc. Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC

No longer forecast to breakeven

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to NT$143

Less than half of directors are independent

Senhwa Biosciences, Inc. Presents Positive Initial Data from Phase 1 Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma at 2022 AAD Annual Meeting

Forecast breakeven date pushed back to 2022

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Senhwa Biosciences, Inc. Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and Other HR Gene Mutations

Us Food and Drug Administration Grants Orphan Drug Designation to Senhwa Biosciences, Inc. for Silmitasertib, A Highly Selective Inhibitor of Casein Kinase 2 (Ck2)

Third quarter 2021 earnings released: NT$0.97 loss per share (vs NT$1.53 loss in 3Q 2020)

Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference

Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Phase 1B Expansion Study of Pidnarulex to Treat Solid Tumors with Specific Homologous Recombination Gene Mutations

Senhwa Biosciences Announces Dose Escalation Initiation of the Phase I Trial of Pidnarulex as a Treatment for Advanced Hematological Malignancies

Senhwa's Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma

Senhwa Announces Ind Submission to India's Cdsco of A Phase II Clinical Study for Silmitasertib as A Potential Covid-19 Treatment

First quarter 2021 earnings released: NT$1.02 loss per share (vs NT$1.13 loss in 1Q 2020)

Full year 2020 earnings released: NT$4.49 loss per share (vs NT$5.26 loss in FY 2019)

Analysts Are Optimistic We'll See A Profit From Senhwa Biosciences, Inc. (GTSM:6492)

New 90-day low: NT$162

Does This Valuation Of Senhwa Biosciences, Inc. (GTSM:6492) Imply Investors Are Overpaying?

New 90-day low: NT$172

Senhwa Biosciences Presents Positive Cholangiocarcinoma Data

Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19

Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

Earnings beat expectations

Third quarter 2020 earnings released: NT$1.52 loss per share

CARE GA Receives Study May Proceed Letter from US FDA to Initiate Phase II Clinical Trial of Senhwa's Silmitasertib in COVID-19 Patients

Senhwa Announces Multiple INDApplication Submissions to U.S. FDA for Silmitasertib as A Potential Treatment for COVID-19

New 90-day high - NT$181

First half earnings released

New 90-day high - NT$180

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento